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Abstract
Objectives. Disease-modifying therapies (DMTs) targeting B cells
are amongst the most effective for preventing multiple sclerosis
(MS) progression. IgG3 antibodies and their uncharacterised B-cell
clones are predicted to play a pathogenic role in MS. Identifying
subsets of IgG3
+ B cells involved in MS progression could improve
diagnosis, could inform timely disease intervention and may lead to
new DMTs that target B cells more specifically. Methods. We
designed a 31-parameter B-cell-focused mass cytometry panel to
interrogate the role of peripheral blood IgG3
+ B cells in MS
progression of two different patient cohorts: one to investigate the
B-cell subsets involved in conversion from clinically isolated
syndrome (CIS) to MS; and another to compare MS patients with
inactive or active stages of disease. Each independent cohort
included a group of non-MS controls. Results. Nine distinct
CD20+IgDIgG3
+ B-cell subsets were identified. Significant changes
in the proportion of CD21+CD24+CD27CD38 and
CD27+CD38hiCD71hi memory B-cell subsets correlated with changes
in serum IgG3 levels and time to conversion from CIS to MS. The
same CD38 double-negative B-cell subset was significantly elevated
in MS patients with active forms of the disease. A third
CD21+CD24+CD27+CD38 subset was elevated in patients with active
MS, whilst narrowband UVB significantly reduced the proportion of
this switched-memory B-cell subset. Conclusion. We have identified
previously uncharacterised subsets of IgG3
+ B cells and shown them
to correlate with autoimmune attacks on the central nervous system
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(CNS). These results highlight the potential for therapies that
specifically target IgG3
+ B cells to impact MS progression.
Keywords: B cells, clinically isolated syndrome, mass cytometry,
multiple sclerosis, phototherapy
INTRODUCTION
Relapsing–remitting multiple sclerosis (RRMS) is an
autoimmune disease caused by the destruction of
the myelin-producing cells in the central nervous
system (CNS). As a consequence of this immune
attack, nerve impulses cannot be transmitted
efficiently and uninterrupted from the CNS to the
periphery. The only successful disease-modifying
therapies (DMTs) limit the damage caused to the
CNS by targeting the cells and molecules of the
immune system. DMTs that target B cells are
proving to be highly effective at halting MS, not
only in RRMS but also notably in progressive
forms of the disease.1 The success of some B-cell-
targeting DMTs such as the anti-CD20 monoclonal
antibodies, rituximab and ocrelizumab, but not
others such as atacicept,2 suggests that not all B
cells are pathogenic in the context of MS. DMTs
targeting specific B-cell subsets that are involved
in MS pathogenesis are likely to be more effective
in the treatment of this CNS disease.
The immunoglobulin subclasses IgG1 and IgG3
have long been associated with autoimmunity,3,4
particularly in MS.5 We recently showed that,
compared with baseline, IgG3 serum levels were
higher in clinically isolated syndrome (CIS) patients
who were close to converting to MS.6 Identification
of the IgG3 B-cell subsets dysregulated by MS will
allow for the design of more targeted therapeutics.
To that end, using mass cytometry to interrogate
circulating IgG3
+ B-cell subsets in two different MS
cohorts, we have discovered nine previously
unidentified subsets of IgG3
+ B cells. CD21+CD24+
CD27CD38 and CD27+CD38hiCD71hi memory
IgG3
+ B cells were found to be significantly
increased as CIS patients progress to MS, which
correlated with increased serum levels of IgG3, and
in patients with active disease. Finally, we show
that phototherapy, which delays progression of CIS
to MS in a subset of individuals,7 is associated with
a significant decrease in CD21+CD24+CD27+
CD38IgG3
+ B-cell subsets mirroring the lower
proportion of IgG3
+ B cells we found in MS patients
with inactive or quiescent disease. Our study
provides evidence that specific IgG3
+ B-cell subsets
are associated with autoimmune attack on the CNS
and that DMTs targeting these subsets may have an
impact on disease progression.
RESULTS
Serum IgG3 levels correlate with the
proportion of IgG3
+ B-cell subsets
Consistent with serum levels of individual IgG
subclasses correlating with IgG+ B cells,8 there was a
statistically significant positive correlation between
IgG3 serum levels and total IgG3
+ B cells (as a
proportion of all B cells, across cohort 1 irrespective
of phototherapy status; Figure 1a). IgG3
+ B cells
could be manually subdivided into nine distinct
subsets based on their expression of CD21, CD20,
CD24, CD27 and CD38 (Figure 1b). The nine IgG3
+
subsets were IgD (Figure 1b) and differed in their
expression of CD71 (transferrin receptor), CD80,
CD185 (CXCR5), CD210 (IL-10 receptor), CD360 (IL-21
receptor) and HLA-DR (Figure 1c). No other markers
were able to differentiate the nine IgG3
+ subsets
(Supplementary figure 1b). Subset 9 had the most
activated phenotype, expressing the highest
amount of HLA-DR, CD71 and CD80. B-cell subset 4,
which resembled double-negative (DN)-1 B cells9 in
that it was IgDCD21+CD24+CD27CXCR5+ but
lacked CD38, showed a statistically significant
positive correlation with IgG3 serum levels
(Figure 1d). The CD27+ memory B-cell subset 9,
which was CD21+ and expressed high levels of CD38
but not CD24, also showed a statistically significant
positive correlation with IgG3 serum levels
(Figure 1e). This suggests that in the PhoCIS cohort,
two B-cell subsets, one with a unique CD38 DN-1
phenotype9 and the other with a subset of CD27+
memory cells, were primarily responsible for
changes in serum IgG3 levels.
Changes in the proportion of IgG3
+ B cells
correlate with time to convert from CIS to
MS and success of DMT
IgG3 serum levels are higher in CIS patients close
to converting to MS.6 The same correlation held
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Figure 1. Serum IgG3 levels correlate with IgG3
+ B-cell subsets. (a) IgG3 serum levels were compared with IgG3
+ B-cell levels (as a proportion of
total B cells). (b) Manual gating strategy progressing from (i) to (iv) and beyond as indicated by the arrows to identify IgG3
+IgDB cells and nine
subsets using CD20, CD21, CD24, CD27 and CD38. (c) tSNE plots showing the position of the nine subsets and heatmap of markers used for
gating and differentiating between these nine subsets. The proportions of subsets (d) 4 and (e) 9 had statistically significant correlations with
IgG3 serum levels. Open black circles represent clinically isolated syndrome (CIS) patients who did not receive phototherapy (n = 8 patients, 25
time points), whilst open black squares represent patients who did receive phototherapy (n = 8 patients, 36 time points). A linear regression was
done (with line shown), with reported P-values and R2-values or q (rho)-value. Mass cytometry data were generated from seven independent
experiments.
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true for IgG3
+ B-cell subsets as there was a
significant increase in total IgG3
+ B cells as CIS
patients went on to develop MS (day 0 being MS
diagnosis) (Figure 2a). B-cell subsets 4 and 9 again
showed a significant correlation as did the CD38+
B-cell subset 5 and an additional CD24 B-cell
subset (subset 2; Figure 2b). For all subsets, MS
disease progression increased the proportion of
IgG3
+ B cells to levels that were comparable to
that of non-MS controls (Figure 2; red line and
shaded areas represent median and interquartile
range of the non-MS controls, respectively;
individual values for non-MS controls are shown
in Supplementary figure 2). Whilst the correlation
between time and relative proportion of IgG3
+ B
cells was lost after conversion to MS (day 0,
dashed vertical line in Figure 2), commencement
of DMTs, dimethyl fumarate (n = 4), natalizumab
(n = 5) or fingolimod (n = 2), reversed the rising
trend in IgG3
+ B cells. This negative correlation
over time was statistically significant for subset 4
(green line, Figure 2b). Indeed, in the absence of
DMT this subset of CD21+CD24+CD27CD38 B
cells continued to rise over time. Together, these
data suggest that there may be an inherent
defect in the IgG3
+ B-cell compartment that is
affected by the course of MS disease and that
DMT can correct this defect. Furthermore, this
IgG3
+ B-cell defect does not seem to be present in
non-MS controls.
Subsets of IgG3
+ B cells increase during
active MS disease
In a second independent cohort of MS patients,
we observed no significant difference in the
proportion of total IgG3
+ B cells comparing iMS,
aMS and non-MS controls (Figure 3a). However,
when we interrogated the nine different subsets
of IgG3
+ B cells, we found that, compared with
inactive disease states, there was a significant
increase in the proportion of B-cell subset 4 in
those with aMS (Figure 3b). This was the same
subset found to be affected by MS progression
and DMT in the PhoCIS cohort (cohort 1;
Figure 2b). CD27+ B-cell subsets 7 and 8 that were
CD21+ and CD21, respectively, were also
significantly higher in patients with aMS
(Figure 3b). Similar to what we observed in the
first cohort, the proportion of all IgG3
+ B-cell
subsets in those with aMS disease was comparable
to that of non-MS controls.
Phototherapy decreases the levels of
circulating IgG3
+ B cells
In the PhoCIS trial, 100% of CIS patients who did
not receive phototherapy converted to MS within
12 months. In contrast, only 70% of CIS patients
who were given phototherapy three times per
week for 8 weeks converted to MS in the
12 months of follow-up.7 Changes in IgG3
+ B-cell
levels (as a proportion of all B cells) were
calculated as the difference in their baseline level.
Compared with control CIS patients, those
receiving phototherapy over the 2-month period
showed a significant reduction in total IgG3
+
B cells (Figure 4a) with subsets 5 and 7 specifically
affected (Figure 4b). Of note, the proportions of
subsets 4 and 9, both of which correlated with
serum IgG3 (Figure 1d), and in the case of subset
4, it was affected by active MS disease (Figure 3b),
were not significantly affected by phototherapy.
DISCUSSION
Using two separate cohorts, we have uncovered a
previously undescribed association for subsets of
IgG3
+ B cells in the conversion of CIS to MS and in
MS patients with a more aggressive disease
course. The serum concentration of IgG3 positively
correlated with the proportion of these peripheral
IgG3
+ B cells (Figure 1a), suggesting that the
source of the elevated IgG3 levels that predict
conversion from CIS to MS are these same B-cell
subsets. Compared with other B cells
(Supplementary figure 1c), almost all IgG3
+ B cells
expressed high levels of CXCR5 (CD185), which is
encoded by a known MS risk gene.10 CXCR5 is the
receptor for CXCL13, a chemokine that mediates
B-cell trafficking into germinal centres, and is
expressed at significantly higher levels in the
cerebrospinal fluid of RRMS patients.11 Whether
CXCR5-expressing IgG3
+ B cells find their way into
the CNS, or exert their effects in lymphoid follicles
remains to be determined.
Two specific subsets that differed in CD27
expression showed the most striking correlation
with serum IgG3 concentrations. Subset 4, which
accounts for 15% of all IgG3
+ B cells in non-MS
controls, expressed CD21 and CD24 but not IgD,
CD27 or CD38, which together with their
expression of CXCR5 makes them phenotypically
similar, but not identical to DN1 B cells (which are
CD38+).9 Whether this difference in CD38
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Figure 2. IgG3
+ B-cell levels positively correlate with CIS conversion to MS. (a) IgG3
+ B-cell levels (as a proportion of total B cells) are shown for
clinically isolated syndrome (CIS) patients as they go on to convert to multiple sclerosis (MS). At time point 0 (vertical dotted line), patients were
diagnosed with MS (prior to this, they had CIS). Open black squares represent CIS patients who received phototherapy (n = 7 patients, 28 time
points), whilst open black circles did not receive phototherapy (n = 5 patients, 27 time points). A linear regression was done, with the line shown
for CIS/prior (black, n = 12 patients, 34 time points) and MS/after with (green, n = 6 patients, 10 time points) or without (purple, n = 9 patients,
11 time points) disease-modifying therapies (DMTs), with the reported P-value and R2-value or q (rho)-value. (b) Subsets of IgG3
+ B cells that had
significant correlations either CIS/prior or MS/after. Solid horizontal red line represents median proportion for non-MS controls, with interquartile
range highlighted in red between dashed horizontal red lines (n = 14 patients). Mass cytometry data were generated from seven independent
experiments.
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expression represents abnormal class switching
and/or germinal centre B-cell maturation in MS is
not known. A decrease in CD38 expression on
double-negative B cells has been described
previously,12 suggesting that subset 4 may be at a
more mature stage of development. IgG3 class
switching, at least in vitro, can be induced by IL-
21,13 and although the IL-21 receptor (CD360) is
associated with MS,14 its expression was absent
from all IgG3
+ subsets except for subset 1. This
lack of IL-21R expression suggests that the IgG3
+ B
cells we found to be associated with MS
progression are likely to be switched-memory B
cells.15 Whether upstream factors such as IL-21
influence the course of MS through IgG3 B-cell
subsets remains to be determined, although both
IL-21 and its receptor are expressed by immune
cells and neurons at greater levels within MS
brains compared with controls.16
Double-negative B cells are broadly defined by
their lack of both IgD and CD27. Supporting our
findings, Fraussen and colleagues recently showed
an increase in IgDCD27 DN-B cells in people
with MS.12 DN1 B cells are thought to represent
an early switched-memory B-cell that still
expresses CD21, CD24 and CD38 but has not yet
acquired CD27.9 In our MS patients, DN1 cells
would correspond to subset 5 (Figure 1c) which in
cohort 1 we found to be positively associated
with conversion of CIS to MS (Figure 2b), and
were one of the only two IgG3
+ B-cell subsets
significantly reduced by phototherapy (Figure 4b).
IgDCD27 DN2 B cells are CD19hiCD21CD24
CD38lowCD185low and would correspond to subset
1 in our analysis (Figure 1c). However, despite
producing the highest amounts of IgG3 in systemic
lupus erythematosus,17 we found no role for
IgG3
+ DN2 B cells in the progression of MS.
We also observed changes in the CD27+ memory
B-cell subset 9, which expressed the highest levels
of CD38, suggesting that it may be a precursor
population to plasmablasts.18,19 Indeed,
CD20+CD27hiCD38hi blood-derived B cells, but not
traditional memory B cells, spontaneously produce
antibodies in vitro.18 Changes in subset 9 would
be consistent with a suspected pathogenic role for
memory B cells in MS.20 Indeed, the proportion of
this IgG3
+ B-cell subset not only correlated with
IgG3 serum levels, but also correlated with
progression from CIS to MS. Memory B-cell subset
9 expressed the highest levels of CD80, HLA-DR
and CD71, the latter being a recently described
early activation marker of proliferating antigen-
specific B cells.21 The functional significance of
high CD71 expression on activated B cells is
unclear. Although we did not find a significant
change in subset 9 within cohort 2, others have
previously shown that CD80+CD71+ leucocytes
(which included B cells) are increased during
active MS.22 CD71, otherwise known as the
transferrin receptor, plays a key role in iron
metabolism, which may be dysregulated in MS.23
Whilst it remains to be seen if targeting
transferrin-bound iron in serum modulates these
CD71-expressing B cells, our data strongly support
the idea that activated IgG3
+ memory B cells are
involved in MS pathogenesis.
Supporting a role for IgG3
+ B-cell subsets in MS
pathogenesis is our observation in a second
cohort that MS patients with clinically confirmed
Figure 3. IgG3
+ B cells are decreased during inactive MS. (a) IgG3
+ B-cell levels as a proportion of total B cells between non-MS controls,
inactive MS (iMS) and active MS (aMS) patients. (b) IgG3
+ B-cell subsets 4, 7 and 8 that had significant differences between disease and control
groups are shown as a proportion of total B cells. As no groups were normally distributed, a non-parametric Kruskal–Wallis test with Dunn’s
multiple comparisons test (median shown) was used with P-values shown. n = 7 or 8 individual patients/controls. Mass cytometry data were
generated from two independent experiments.
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active forms of the disease also had significantly
elevated levels of specific IgG3
+ subsets. IgG3
+ B-
cell subset 4 was again implicated in this cohort,
and management of MS disease in cohort 1
through administration of DMTs known to affect
B cells including dimethyl fumarate,24,25
natalizumab26 and fingolimod27,28 was associated
with lower proportions of this IgG3-expressing
subset. Although phototherapy did not
significantly suppress the conversion of CIS to
MS,7 exposure to narrowband UVB does lead to a
significant but short-lived decrease in circulating
CD20+CD27+IgD B cells as a proportion of total B
cells.29 Here, we have discovered using mass
cytometry that these UVB-targeted ‘switched-
memory’ B cells are likely to include a population
Figure 4. Phototherapy decreases IgG3
+ B-cell proportions in CIS patients. IgG3
+ B-cell levels (as a proportion of total B cells) were compared
between clinically isolated syndrome (CIS) patients who either received phototherapy for 2 months and CIS patients who did not. (a) The change
in IgG3
+ B cells compared with baseline prior to phototherapy. CIS patients who received phototherapy are indicated in red, whilst CIS patients
who did not are indicated in black open circles. A linear regression was done with shown P-values and R2-values for CIS patients who did not
receive phototherapy (black) or did receive phototherapy (red). Slopes of linear regression lines were compared between groups, by a comparable
analysis of covariance (ANCOVA) with the P-value reported in a black box. (b) Subsets of IgG3
+ B cells that had significant differences between
CIS patients who did or did not receive phototherapy. n = 8 individual patients. Mass cytometry data were generated from seven independent
experiments.
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of IgG3
+ B cells (subset 7; Figure 4b). This same
population of IgG3
+ B cells were significantly
elevated in those with active forms of MS that
subsequently have been found to be more
aggressive (Figure 3b), suggesting that this subset
is also involved in MS progression.
It is not entirely clear what role IgG3 plays in
MS pathogenesis. IgG3 has the highest affinity for
the complement protein C1q30 and is
consequently a potent activator of the classical
complement pathway.31,32 Complement proteins
C1q and C3 are present in demyelinated MS
lesions,33-37 and the membrane attack complex,
which represents the end stage of complement
activation, has been found surrounding myelin.33
Thus, IgG3 and the B cells that produce it are
likely to be involved in complement-mediated MS
pathogenesis. Our findings suggest that reducing
circulating IgG3 or specific subsets of B cells that
produce IgG3 may inhibit MS disease activity. CIS
patients receiving phototherapy had an overall
decrease in circulating IgG3
+ B cells, as well as
select IgG3
+ B-cell subsets. Phototherapy delays
the onset of MS in a subset of CIS patients,7 and
exposure to UV radiation (UVR) decreases the
expression of classical complement genes
including C1q.38 These two UVR-driven events
may work synergistically to lower IgG3
complement-mediated damage in MS, which may
explain the observations from epidemiological39
and animal studies40 that UVR protects from MS.
In the PhoCIS cohort, we noticed, somewhat
paradoxically, that as CIS patients progressed to
MS, the proportion of circulating IgG3
+ B cells rose
to levels that were similar to that found in non-
MS controls. This was also observed in the second
cohort whereby proportions of IgG3
+ B cells in
those with iMS were significantly lower than
those of non-MS controls despite not being on
any DMT at the time of blood sampling. However,
in untreated MS patients with active disease, their
proportions were no longer different from non-
MS controls. This suggests that whilst people
without CIS or MS do have IgG3
+ B cells, they are
presumably not producing IgG3 antibodies either
to autoantigens or pathogens, which may have
implications for viral defence. IgG3 has the most
flexible and extended hinge region of all the IgG
isotypes.41 It contains multiple glycosylation sites
and has a high affinity for Fcc receptors,
particularly CD16a,42 which is highly expressed by
NK cells and monocytes/macrophages, and IgG3 is
the most potent activator of classical
complement.31,32 This makes IgG3, despite only
accounting for 5–8% of total IgG in the
circulation, an important immunological player,
especially in response to infectious diseases.43
What our data show is that in those susceptible to
MS, subsets of IgG3
+ B cells are abnormally low
during inactive disease states. However, during
periods of progression or relapse, these B cells are
activated to clonally expand from a low level and
differentiate to secrete IgG3 into the circulation.
This may indicate that there is an inherent defect
in the IgG3
+ B-cell compartment in those at risk of
MS with abnormally low levels of IgG3 increasing
the susceptibility to certain infections and/or
autoreactive IgG3 B-cell clones being activated to
secrete autoantibodies.
In conclusion, mass cytometry has provided us
with unprecedented insight into the changes that
occur in IgG3
+ B cells as CIS patients convert to
MS, and when MS patients develop active forms
of the disease. Our results highlight that
interventions (e.g. phototherapy) that reduce
these populations of IgG3
+ B cells protect CIS
patients from transitioning to MS. These findings
justify consideration for subsets of IgG3
+ B cells as
biomarkers and/or mediators of disease
progression in MS, as well as future targets of
novel immunotherapies.
METHODS
Study participants: cohort 1 – CIS/MS/
phototherapy patients
Recruitment of these patients was conducted in Perth,
Western Australia. The Phototherapy for Clinically Isolated
Syndrome (PhoCIS) trial design has been published.7 Briefly,
16 of the 20 individuals (10 females: range 29–54, median
43 years old; and six males: range 27–42, median 36 years
old) presenting with CIS within 120 days from their first
demyelinating event at study enrolment, and meeting
PatyA or PatyB criteria based on magnetic resonance
imaging (MRI) were included. Insufficient biobanked cells
were available from the other 4 trial participants. All
participants with CIS were drug-na€ıve, but if they did not
have 25(OH)D levels > 80 nmol L1 at enrolment, they were
supplemented with oral vitamin D.7 MRI scans and clinical
assessments were performed at 3, 6 and 12 months after
enrolment to detect conversion to MS, the diagnosis of
which was based on the appearance of new MRI-confirmed
lesions. Following the detection of new lesions and
confirmation of a diagnosis of MS, patients were offered
one of three DMTs: dimethyl fumarate, natalizumab or
fingolimod. Non-MS controls (n = 14) were age- and sex-
matched to the patient group and were free of
neurological signs/symptoms.
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The PhoCIS study was carried out in accordance with the
recommendations of the National Health and Medical
Research Council of Australia’s National Statement on
Ethical Conduct in Human Research. The PhoCIS study
protocol was approved by the Bellberry Human Research
Ethics Committee (2014-02-083) and endorsed by the
Human Research Ethics Office of the University of Western
Australia (RA/4/1/6796), and the study of MS participants
was approved by Sir Charles Gairdner Hospital Human
Research Ethics Committee (2006-073). All participants gave
written informed consent in accordance with the
Declaration of Helsinki prior to study procedures being
performed.
Phototherapy intervention
In the PhoCIS trial, CIS participants were randomised to
receive (n = 8), or not receive (controls, n = 8), narrowband
UVB phototherapy three times per week for the first
8 weeks (24 sessions in total). Phototherapy was delivered
according to the Dundee protocol, based on patient skin
type as previously described.7
Blood sampling
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinised blood collected in lithium heparin
vacutainers (BD) using a Lymphoprep (Axis-Shield, Oslo,
Norway) density separation gradient. The CIS patients
(n = 16) from the PhoCIS trial had their peripheral venous
blood taken at 1 week, 1 month, 2 months, 3 months,
6 months and 12 months post-baseline. PBMC were
cryopreserved in 5–10% DMSO/FBS for storage in liquid
nitrogen prior to mass cytometry staining.
Cytometric bead array for IgG3 serum levels
IgG3 serum levels were measured using cytometric bead
arrays (BD Biosciences, North Ryde, NSW, Australia), with
data captured using the BD LSRFortessa flow cytometer,
according to the manufacturer’s instructions and as
previously described.6
Study participants: cohort 2 – inactive and
active MS patients and non-MS controls
Ethical consent for the study was obtained from the
Research Integrity and Ethics Administration of the
University of Sydney (project number 2012/1851). Multiple
sclerosis was defined by McDonald 2010 criteria, and
disease activity was defined by neurological signs/symptoms
and the presence of new T2 or gadolinium-enhancing MRI
lesions. No patients were on DMTs at the time of blood
sampling. All patients had low disability (EDSS range 0–2.5).
Cohort 2 patient data are shown in Table 1.
Inactive MS (iMS, n = 8) was defined as having no
disease activity in the previous 6 months of blood
sampling, a low lesion load, and in follow-up, these
patients have had a benign clinical course, a number never
having been started on DMTs. Six of eight iMS patients
had not been on DMTs prior to blood collection. Active
MS (aMS, n = 7) was defined as having disease activity
within 6 months of blood sampling and subsequently an
aggressive clinical course; all patients having ended up on
high-efficacy DMT since the blood collection. Six of
seven aMS patients had not been on therapeutics prior to
blood collection. Non-MS controls (n = 8) were age- and
sex-matched to the patient cohort and were free of
neurological signs/symptoms.
Blood sampling
PBMC were isolated from blood and collected in EDTA
vacuette tubes (Greiner Bio-One International,
Kremsm€unster, Austria) using a Ficoll-Paque Plus (GE
Healthcare, Chicago, IL, USA) density separation gradient.
Samples were cryopreserved in 5–10% DMSO/FBS for storage
in liquid nitrogen prior to mass cytometry staining.
Cell staining and analysis by mass
cytometry
A total of 2.5–5 9 106 cells were resuscitated by thawing in
a 37°C water bath and washed in RPMI medium. Individual
patient/time point samples were first barcoded with anti-
human CD45 (on three different metal isotopes) for
30 min, such that three independent samples could be
combined for further staining as described.44 Samples were
combined (for 7.5–15 9 106 cells) and stained with cisplatin
(Fluidigm, South San Francisco, CA, USA) for 5 min as a
live/dead marker. PBMC were stained with antibodies
specific for the markers in Table 2 for 30 min. These
antibodies were purchased unlabelled in a carrier-protein-
free medium and conjugated with the indicated metal
isotope using the x8 MaxPAR conjugation kit (Fluidigm)
according to the manufacturer’s protocol. Conjugations
done by the Ramaciotti Facility for Human Systems Biology
are indicated in Table 2. Cells were fixed in 4%
paraformaldehyde (PFA) for 20 min prior to being
incubated in Foxp3 permeabilisation buffer (eBioscience
Inc., San Diego, CA, USA) for 15 min. Cells were finally
resuspended in DNA intercalator mix [1/1000 iridium
intercalator (Fluidigm) in 4% PFA] and washed with Milli-Q
water before being resuspended in 10% EQ four element
beads (Fluidigm) in Milli-Q water at a concentration of
0.8 9 106 cells mL1, to be run on a CyTOF 2 Helios mass
cytometer (Fluidigm).
Samples were initially gated as shown in Supplementary
figure 1a using FlowJo v10.4 (Becton Dickinson, Ashland,
OR, USA). All analyses were done on CD3, HLA-DR+,
CD19dim/hi, IgG4 and IgG3+ B cells. tSNE plots were
generated using the following markers: CD19, CD20, CD21,
CD23, CD24, CD25, CD27, CD38, CD71, CD79b, CD80, CD86,
CD120a, CD120b, CD138, CD184, CD185, CD210, CD267,
CD274, CD360, HLA-DR, 5 HT2A, PAF-R, S1P1 and membrane
TNF (Table 2). Markers not expressed on IgG3
+ B cells (CD3,
IgD, IgE and IgG4) and CD45 (used as a barcode) were not
included in generating the tSNE plot. Although IgM was
included in the panel design, it needed to be excluded
from the final analysis because of quality control issues
with staining in this channel. tSNE plot was generated
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using the script Cytometry Analysis Pipeline for large and
complex data sets (CAPX)45 in R, after downsampling for a
total of 10 000 cells. tSNE parameters included 1000
iterations with a perplexity of 30 and theta of 0.5. Subsets
of IgG3
+ B cells were gated manually in FlowJo.
Statistical analysis: cohort 1
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, San Diego, CA, USA) version
8.2.1. A P-value < 0.05 was considered statistically significant.
IgG3 serum analysis
Patient samples were combined for analysis purposes
regardless of phototherapy treatment. For IgG3 serum
comparison, eight control patients (with 25 time points)
and eight phototherapy patients (with 36 time points) were
included in the analyses. If data passed a Shapiro–Wilk
normality test, then a parametric Pearson correlation
coefficient was used (and R2-value was shown). If the data
were not normally distributed, a non-parametric Spearman
correlation was done and a q (rho)-value is shown.
Days to conversion analysis
IgG3
+ B-cell levels in CIS patients who converted to MS
irrespective of phototherapy were compared. Three
phototherapy patients did not go on to develop MS during
the 12-month study so were not included in the analysis,
whilst one control patient (no phototherapy) dropped out
of the study so disease status is not known. This left
seven control patients (with 28 time points) and
5 phototherapy patients (with 27 time points). Once again,
a Shapiro–Wilk normality test was done across all time
points (either 34, 11 after without DMT or 10 after with
DMT) to determine distribution of data. If data passed, a
parametric Pearson correlation coefficient was used (and a
R2-value is shown). If the data were not normally
distributed, a non-parametric Spearman correlation was
done (and a q (rho)-value is shown).
Phototherapy analysis
CIS patients received phototherapy for the first 8 weeks
(2 months) of the study with blood being analysed at
baseline, 1 week (phototherapy only), 1 month (phototherapy
Table 1. Cohort 2 patient data
Non-MS controls (n = 8) iMS (n = 8) aMS (n = 7)
Median age (range) 40 (25–59) 50 (27–60) 32 (25–42)
Female sex 5 (62.5%) 7 (87.5%) 6 (85.7%)
Median EDSS (range)
Prior treatment –– 0 (0–1) 0 (0–1)
Current –– 0 (0–0) 0 (0–2.5)
Previous treatment prior to blood sampling
Time since last dose
Untreated –– 6 6
1 month –– 1 0
2 years –– 0 1
10 years –– 1 0
Disease-modifying therapy
Untreated –– 6 6
IFN-b –– 2 1
Clinical/MRI activity prior to blood collection
Sensory symptoms > 1 year –– 3 0
No symptoms > 9 months –– 3 0
No disease activity > 4 years –– 2 0
Activity < 6 months –– 0 7
Lesion load
Brain
Low –– 7 4
Moderate –– 1 1
High –– 0 2
Spinal
No –– 2 1
Yes –– 6 3
Several –– 0 1
Enhancing –– 0 1
Large + thoracic cord lesion –– 0 1
Other characteristics
Pars planitis –– 1 0
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only) and 2 months post-treatment. Five no phototherapy
(with 10 time points) and seven phototherapy (with 23 time
points) patients were included for analysis. A linear regression
was done to compare changes in proportion of IgG3
+ B cells
compared with baseline over time for each group.
Phototherapy and no phototherapy groups were then
compared with a comparable analysis of covariance
(ANCOVA).
Statistical analysis: cohort 2 – iMS, aMS and
non-MS analysis
A Shapiro–Wilk normality test was first done across all
groups to determine the distribution of data. Only if all
three groups (non-MS, iMS and aMS) passed was a
parametric one-way ANOVA (with Tukey’s multiple
comparisons test) used. If any one group failed the
normality test, a non-parametric Kruskal–Wallis test (with
Dunn’s multiple comparisons test) was performed.
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CD120a 158Gd REA252 Miltenyi Biotec U
CD120b 160Gd 3G7A02 BioLegend U
CD138 150Ndc DL-101 BioLegend U
CD184 (CXCR4) 175Luc 12G5 BD Biosciences U
CD185 (CXCR5) 146Nd J252D4 BioLegend U
CD210 (IL-10 receptor) 169Tm REA239 Miltenyi Biotec U
CD267 (TACI) 159Gd 1A1 BioLegend U
CD274 (PD-L1) 161Dy 29E.2A3 BioLegend U
CD360 (IL-21 receptor) 165Ho REA233 Miltenyi Biotec U
HLA-DR 174Ybc L243 BD Biosciences U
IgD 89Yc IA6-2 BD Biosciences
IgE 148Nd MHE-18 BioLegend
IgG3 145Nd HP6047 BioLegend
IgG4 168Er HP6023 BioLegend
5-HT2A receptor 166Er Polyclonal Novus Biologicals U
PAF receptor 163Dy AA14 (clone21) Cayman Chemicals U
S1P1 170Er MM0045-21L9 Novus Biologicals U
TNF (membrane) 141Prc Mab11 BioLegend U
a
Markers used to run tSNE plots.
b
Markers used for gating IgG3
+ B-cell subsets.
c
Isotopes conjugated by the Ramaciotti Facility for Human Systems Biology, The University of Sydney, Australia.
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